Trial Profile
A phase 2 study of cyclophosphamide, lenalidomide and dexamethasone (CRD) for patients with relapsed/refractory multiple myeolma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 May 2016
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 05 Apr 2013 New trial record